scholarly journals Glycosaminoglycans in the urinary bladder mucosa, tumor tissue and mucosal tissue around tumor

2012 ◽  
Vol 69 (2) ◽  
pp. 147-150 ◽  
Author(s):  
Nebojsa Bojanic ◽  
Djordje Nale ◽  
Sava Micic ◽  
Natasa Lalic ◽  
Aleksandar Vuksanovic ◽  
...  
Keyword(s):  
Urinary Bladder ◽  
Bladder Carcinoma ◽  
Bladder Tumor ◽  
Tumor Tissue ◽  
Tumor Grade ◽  
Cellular Membrane ◽  
Muscular Tissue ◽  
Healthy Individuals ◽  
Bladder Mucosa ◽  
Tissue Samples

Introduction/Aim. Glycosaminoglycans (GAG) are one of the main constituents of the connective tissue and cellular membrane. Their presence has been evidenced in mucosa and muscular tissue of the urinary bladder of both healthy individuals and those affected by carcinoma. This suggest their potential role in the onset of bladder carcinoma and follow-up of those patients. The aim of the study was to determine GAG levels in tumor tissue and the surrounding bladder mucosa in patients with bladder tumor, as well as in the bladder mucosa in patients with bladder carcinoma, and to compare the results according to the grade and stage of tumor and relapse. Methods. Tissue samples were taken in 61 patients (48 males and 13 females), mean age 61.5 years, range 40-92 years, obtained by transurethral resection (TUR) of bladder tumor, and 8 healthy persons. Determination of a total GAG content in the tissue samples was done by the Whiteman's method and then compared regarding the tumor grade and stage. Results. Tumor grade and stage directly correlated with the levels of GAG. The GAG levels were significantly higher in tumor samples as compared to healthy mucosa. Conclusion. Higher GAG levels were recorded in all the patients with bladder tumors comparing to smples obtained from healthy individuals. GAG levels do not predict tumor relapse.

A HISTOPATHOLOGICAL STUDY OF BLADDER TUMORS

2021 ◽  
pp. 5-7
Author(s):  
Mansi Khamesra ◽  
Lavish Tayal ◽  
Bhavana Garg ◽  
Vijaya Mysorekar
Keyword(s):  
Urinary Bladder ◽  
Bladder Carcinoma ◽  
Bladder Tumor ◽  
Histopathological Study ◽  
Lateral Side ◽  
Urinary Bladder Carcinoma ◽  
Common Symptom ◽  
High Grade ◽  
Bladder Tumors ◽  
Histopathological Type

Background: The bladder is a common site for urinary tract malignancy. Urinary bladder carcinoma is of global concern and the histopathological types and variants are of relevance for their management. This study was carried out to assess the histopathological characteristics of bladder tumors. Materials and methods: The data was collected retrospectively and prospectively to include a total of 140 urinary bladder tumor specimens. Detailed medical records of these subjects were collected, and histopathological examination was performed on the prospective samples. Results: The most common symptom of bladder tumor was hematuria. Cystoscopy results found grossly visible tumor growths in about 76% subjects. Of the total sample, 84% patients underwent transurethral resection of bladder tumor (TURBT) surgery and the rest of them underwent cystectomy. Furthermore, the commonest histopathological type of urinary bladder carcinoma was invasive urothelial carcinoma. About 68.6% patients had high grade tumor. Most tumor growths were present on the lateral side (46.43%). In 52.86% specimens, deep muscles were involved in the tumor. Node involvement was positive in 11 (47.83%) patients. As per TNM classication, majority of the specimens were pT2bN2Mx (26.09%) and pT2bN0Mx (5, 21.74%). Tumors were detected in stage 2 (26.09%), stage 3 (30.43%) and stage 4 (39.13%). Conclusions: The most common symptom observed in patients with urinary bladder carcinoma was hematuria. Cystoscopy results found 75.71% subjects to have grossly visible tumor growths. The major histopathological type of bladder carcinoma was invasive. In 52.86% specimens, deep muscles were involved in the tumor. About 68.6% patients had high grade tumor.

scholarly journals Metadherin (MTDH) Overexpression Significantly Correlates with Advanced Tumor Grade and Stages among Colorectal Cancer Patients

2021 ◽  
Author(s):  
Aimen Sultan ◽  
Namood-e Sahar ◽  
Syeda Kiran Riaz ◽  
Javeria Qadir ◽  
Shahzad Hussain Waqar ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Progression ◽  
Tumor Tissue ◽  
Tumor Grade ◽  
Ki 67 ◽  
Core Element ◽  
Age And Gender ◽  
Tissue Samples ◽  
Advanced Tumor ◽  
And Gender

Abstract BackgroundColorectal cancer is the 4th leading cause of cancer related deaths affecting both men and women worldwide. In the present study, any probable role of MTDH mRNA expression in CRC tumorigenesis was explored using both discovery and validation cohorts. Methods and resultsAfter prior ethical and biosafety approvals, tumor tissue samples along with their adjacent controls were collected for this study from Pakistani patients diagnosed with colorectal cancer. RNA was isolated using Trizol reagent, followed by cDNA synthesis. Transcript analysis of MTDH was performed by using qPCR. Moreover, genome-wide expression of MTDH was also determined through micro-array data analysis using BRB- Array Tools software. MTDH expression was significantly high in tumor tissue samples (p<0.05) compared to their respective controls. Likewise, results of microarray analysis also revealed overamplification of MTDH in tumor samples as compared to controls. Expression of MTDH was also found to be positively correlated with KI-67 index (p<0.05) and were observed to be significantly upregulated in advance tumor grade (p< 0.05) and stage (p< 0.05). However, no association of MTDH overexpression with age and gender could be established. ConclusionHence, it can be concluded that MTDH is a core element that plays a pivotal role in colorectal tumorigenesis irrespective of patient’s age and gender. Molecular insight into the tumor microenvironment revealed MTDH as a niche, representing distinctive framework for cancer progression, thus, making it an innovative target strategy for colorectal cancer treatment.

Invasive ultrasound interventions in tumors of the urinary bladder and prostate

1997 ◽  
Vol 78 (3) ◽  
pp. 204-206
Author(s):  
A. Yu. Zubkov
Keyword(s):  
Urinary Bladder ◽  
Bladder Carcinoma ◽  
Tumor Invasion ◽  
Bladder Tumor ◽  
Urinary Bladder Carcinoma ◽  
Interventional Ultrasound ◽  
Urinary Bladder Tumor

The transperioral biopsy of the prostate under sonographic control is performed in 13 patients. The urinary bladder carcinoma is revealed in 4 patients and adenocarcinoma is revealed in 9 patients. The transcutaneous paracentetic nephrostomy under ultrasound control being an effective method of supravesical urine lead is performed in 23 patients with retentional and obstructive affection of upper urinaiy tracts as a result of the urinary bladder tumor invasion. The interventional ultrasound tactics in patients with tumors of the urinary bladder and prostate is perspective.

A Novel Method for Microsatellite Instability Detection by Liquid Biopsy Based on Next- Generation Sequencing

2020 ◽  
Vol 15 ◽  
Author(s):  
Zheng Jiang ◽  
Hui Liu ◽  
Siwen Zhang ◽  
Jia Liu ◽  
Weitao Wang ◽  
...  
Keyword(s):  
Next Generation Sequencing ◽  
Microsatellite Instability ◽  
Liquid Biopsy ◽  
Tumor Tissue ◽  
High Sensitivity ◽  
Next Generation ◽  
Tissue Samples ◽  
Next Generation Sequencing Technology ◽  
Medication Selection ◽  
Generation Sequencing

Background: Microsatellite instability (MSI) is a prognostic biomarker used to guide medication selection in multiple cancers, such as colorectal cancer. Traditional PCR with capillary electrophoresis and next-generation sequencing using paired tumor tissue and leukocyte samples are the main approaches for MSI detection due to their high sensitivity and specificity. Currently, patient tissue samples are obtained through puncture or surgery, which causes injury and risk of concurrent disease, further illustrating the need for MSI detection by liquid biopsy. Methods: We propose an analytic method using paired plasma/leukocyte samples and MSI detection using next-generation sequencing technology. Based on the theoretical progress of oncogenesis, we hypothesized that the microsatellite site length in plasma equals the combination of the distribution of tumor tissue and leukocytes. Thus, we defined a window-judgement method to identify whether biomarkers were stable. Results: Compared to traditional PCR as the standard, we evaluated three methods in 20 samples (MSI-H:3/MSS:17): peak shifting method using tissue vs. leukocytes, peak shifting method using plasma vs. leukocytes, and our method using plasma vs. leukocytes. Compared to traditional PCR, we observed a sensitivity of 100%, 0%, and 100%, and a specificity of 100.00%, 94.12%, and 88.24%, respectively. Conclusion: Our method has the advantage of possibly detecting MSI in a liquid biopsy and provides a novel direction for future studies to increase the specificity of the method.

scholarly journals Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Stine Karlsen Oversoe ◽  
Michelle Simone Clement ◽  
Britta Weber ◽  
Henning Grønbæk ◽  
Stephen Jacques Hamilton-Dutoit ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Mutation Rate ◽  
Detection Rate ◽  
Tumor Tissue ◽  
Circulating Tumor Dna ◽  
Treatment Modalities ◽  
Advanced Hepatocellular Carcinoma ◽  
Tissue Samples ◽  
The Impact ◽  
Tumor Dna

Abstract Background and aims Studies suggest that mutations in the CTNNB1 gene are predictive of response to immunotherapy, an emerging therapy for advanced hepatocellular carcinoma (HCC). Analysis of circulating tumor DNA (ctDNA) offers the possibility of serial non-invasive mutational profiling of tumors. Combining tumor tissue and ctDNA analysis may increase the detection rate of mutations. This study aimed to evaluate the frequency of the CTNNB1 p.T41A mutation in ctDNA and tumor samples from HCC patients and to evaluate the concordance rates between plasma and tissue. We further evaluated changes in ctDNA after various HCC treatment modalities and the impact of the CTNNB1 p.T41A mutation on the clinical course of HCC. Methods We used droplet digital PCR to analyze plasma from 95 patients and the corresponding tumor samples from 37 patients during 3 years follow up. Results In tumor tissue samples, the mutation rate was 8.1% (3/37). In ctDNA from HCC patients, the CTNNB1 mutation rate was 9.5% (9/95) in the pre-treatment samples. Adding results from plasma analysis to the subgroup of patients with available tissue samples, the mutation detection rate increased to 13.5% (5/37). There was no difference in overall survival according to CTNNB1 mutational status. Serial testing of ctDNA suggested a possible clonal evolution of HCC or arising multicentric tumors with separate genetic profiles in individual patients. Conclusion Combining analysis of ctDNA and tumor tissue increased the detection rate of CTNNB1 mutation in HCC patients. A liquid biopsy approach may be useful in a tailored therapy of HCC.

scholarly journals Soluble cytotoxic T-lymphocyte–associated antigen 4 (sCTLA-4) as a potential biomarker for diagnosis and evaluation of the prognosis in Glioma

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Jiajia Liu ◽  
Xiaoyi Tian ◽  
Yan Wang ◽  
Xixiong Kang ◽  
Wenqi Song
Keyword(s):  
T Lymphocyte ◽  
Roc Curve ◽  
Cytotoxic T Lymphocyte ◽  
Tumor Grade ◽  
Curve Analysis ◽  
Enzyme Linked Immunosorbent Assay ◽  
Low Grade ◽  
High Grade ◽  
Healthy Individuals ◽  
Roc Curve Analysis

Abstract Background The cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) is widely considered as a pivotal immune checkpoint molecule to suppress antitumor immunity. However, the significance of soluble CTLA-4 (sCTLA-4) remains unclear in the patients with brain glioma. Here we aimed to investigate the significance of serum sCTLA-4 levels as a noninvasive biomarker for diagnosis and evaluation of the prognosis in glioma patients. Methods In this study, the levels of sCTLA-4 in serum from 50 patients diagnosed with different grade gliomas including preoperative and postoperative, and 50 healthy individuals were measured by an enzyme-linked immunosorbent assay (ELISA). And then ROC curve analysis and survival analyses were performed to explore the clinical significance of sCTLA-4. Results Serum sCTLA-4 levels were significantly increased in patients with glioma compared to that of healthy individuals, and which was also positively correlated with the tumor grade. ROC curve analysis showed that the best cutoff value for sCTLA-4 for glioma is 112.1 pg/ml, as well as the sensitivity and specificity with 82.0 and 78.0%, respectively, and a cut-off value of 220.43 pg/ml was best distinguished in patients between low-grade glioma group and high-grade glioma group with sensitivity 73.1% and specificity 79.2%. Survival analysis revealed that the patients with high sCTLA-4 levels (> 189.64 pg/ml) had shorter progression-free survival (PFS) compared to those with low sCTLA-4 levels (≤189.64 pg/ml). In the univariate analysis, elder, high-grade tumor, high sCTLA-4 levels and high Ki-67 index were significantly associated with shorter PFS. In the multivariate analysis, sCTLA-4 levels and tumor grade remained an independent prognostic factor. Conclusion These findings indicated that serum sCTLA-4 levels play a critical role in the pathogenesis and development of glioma, which might become a valuable predictive biomarker for supplementary diagnosis and evaluation of the progress and prognosis in glioma.

Sign in / Sign up

Export Citation Format

Share Document